Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Safe & Effective Treatment
CAS Number: 137525-51-0 Molecular Formula: C62H98N15O22 Molecular Weight: 1419.556 g/mol 99% Purity Stored at -20 in medical-grade freezers Research Grade Laboratory research use only References Jzwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P
Whats included Complete self-injection kit with sharps box, gauze, swabs, syringes and needles
US$ 21.27
US$ 21.42
US$ 27.42
US$ 24.53
US$ 29.02
